Redeye: Asarina Pharma - Moment of Truth

Redeye considers the results of Asarina Pharma’s phase IIb trial, to be presented at the end of April, as one of the highlights on the Scandinavian biotech scene this year. We set the likelihood for a positive outcome to 50 percent in the phase IIb trial and see an attractive risk/reward at current share levels.

Read more and download the research update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.